Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/30537
Title: Antiretroviral Therapy for the Prevention of HIV-1 Transmission
Authors: Cohen, Myron S
Chen, Ying Q
McCauley, Marybeth
Gamble, Theresa
Hosseinipour, Mina C
Kumarasamy, Nagalingeswaran
Hakim, James G
Kumwenda, Johnstone
Grinsztejn, Beatriz
Pilotto, Jose H S
Godbole, Sheela V
Chariyalertsak, Suwat
Santos, Breno R
Mayer, Kenneth H
Hoffman, Irving F
Eshleman, Susan H
Piwowar-Manning, Estelle
Cottle, Leslie
Zhang, Xinyi C
Makhema, Joseph
Mills, Lisa A
Panchia, Ravindre
Faesen, Sharlaa
Eron, Joseph
Gallant, Joel
Havlir, Diane
Swindells, Susan
Elharrar, Vanessa
Burns, David
Taha, Taha E
Nielsen-Saines, Karin
Celentano, David D
Essex, Max
Hudelson, Sarah E
Redd, Andrew D
Fleming, Thomas R
HPTN 052 Study Team
Affilliation: ver em Notas
Abstract: An interim analysis of data from the HIV Prevention Trials Network (HPTN) 052 trial showed that antiretroviral therapy (ART) prevented more than 96% of genetically linked infections caused by human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. ART was then offered to all patients with HIV-1 infection (index participants). The study included more than 5 years of follow-up to assess the durability of such therapy for the prevention of HIV-1 transmission.
Keywords: HIV
Anti-Retroviral Agents
Sexual Partners
Disease Transmission, Infectious
Issue Date: 2016
Publisher: Massachusetts Medical Society
Citation: COHEN, M. S. et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. New England journal of medicine, v. 375, n. 9, p. 830-839, 2016.
Description: Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., M.C.H., I.F.H., J.E.); the Divisions of Vaccine and Infectious Disease (Y.Q.C., X.C.Z.) and Public Health Science (Y.Q.C.) and the Statistical Center for HIV/AIDS Research and Prevention (L.C.), Fred Hutchinson Cancer Research Center, and the Department of Biostatistics, University of Washington (T.R.F.) — both in Seattle; FHI 360, Washington, DC (M.M.), and Durham, NC (T.G.); Y.R. Gaitonde Center for AIDS Research and Education, Chennai (N.K.), and National AIDS Research Institute, Pune (S.V.G.) — both in India; University of Zimbabwe, Harare (J.G.H.); College of Medicine–Johns Hopkins Project, Blantyre, Malawi (J.K.); Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS (B.G.) and Hospital Geral de Nova Iguaçu./ Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular (J.H.S.P.), Rio de Janeiro, and Servico de Infectologia, Hospital Nossa Senhora da Conceicao/GHC, Porto Alegre (B.R.S.) — both in Brazil; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand (S.C.); Fenway Institute (K.H.M.) and Harvard School of Public Health (M.E.) — both in Boston; the Departments of Pathology (S.H.E., E.P.-M., S.E.H.) and Medicine (A.D.R.), Johns Hopkins University School of Medicine, the Department of Epidemiology, Bloomberg School of Public Health (T.E.T.), and Johns Hopkins Bloomberg School of Public Health (D.D.C.), Baltimore, and the Division of AIDS (V.E., D.B.) and Laboratory of Immunoregulation (A.D.R.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda — both in Maryland; Botswana Harvard AIDS Institute, Gaborone (J.M.); Centers for Disease Control and Prevention (CDC) Division of HIV/AIDS Prevention/KEMRI– CDC Research and Public Health Collaboration HIV Research Branch, Kisumu, Kenya (L.A.M.); Perinatal HIV Research Unit (R.P.) and Clinical HIV Research Unit, Department of Medicine, Faculty of Health Sciences (S.F.), University of the Witwatersrand, Johannesburg; Southwest CARE Center, Santa Fe, NM (J.G.); University of California, San Francisco, San Francisco (D.H.); University of Nebraska Medical Center, Omaha (S.S.); and the Division of Infectious Diseases, David Geffen UCLA School of Medicine, Los Angeles (K.N.-S.).HPTN 052 - HIV Prevention Trials Network. HPTN 052 enrolled 1,763 HIV sero-discordant couples – where one person is HIV-infected and the other is not – at 13 sites in nine countries. The majority of the couples were heterosexual (97%).
DOI: 10.1056/NEJMoa1600693
ISSN: 0028-4793
Copyright: open access
Appears in Collections:INI - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
Antiretroviral Therapy_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2016.pdf325.52 kBAdobe PDFView/Open


FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.